Cancer Chemother Pharmacol (2016) 77:1153–1155 DOI 10.1007/s00280-016-3016-8

ERRATUM

Erratum to: Phase II trial of biweekly docetaxel, cisplatin, and 5‑fluorouracil chemotherapy for advanced esophageal squamous cell carcinoma Yoshihiro Tanaka1 · Kazuhiro Yoshida1 · Atsuko Yamada1 · Toshiyuki Tanahashi1 · Naoki Okumura1 · Nobuhisa Matsuhashi1 · Kazuya Yamaguchi1 · Tatsuhiko Miyazaki2 

Published online: 25 April 2016 © Springer-Verlag Berlin Heidelberg 2016

Erratum to: Cancer Chemother Pharmacol DOI 10.1007/s00280‑016‑2985‑y Unfortunately, the online published article has error in Table 5. The correct Table 5 is given here. The original article has been corrected.

The online version of the original article can be found under doi:10.1007/s00280-016-2985-y. * Yoshihiro Tanaka [email protected] 1

Department of Surgical Oncology, Gifu Graduate School of Medicine, 1‑1 Yanagido, Gifu 501‑1194, Japan

2

Department of Pathology, Gifu University Hospital, Gifu, Japan



13

13

Watanabe [37]

Hara [36]

Ferri [35]

Tamura [34]

Yamasaki [23]

Osaka [33]

D: 50 (day 1) C: 70 (day 1) F: 700 (days 1–5)/3 wks D: 60 (day 1) C: 60 (day 1) F: 800 (days 1–5)/3–4 wks × 2 courses D: 70 (day 1) Esophageal C: 70 (day 1) cancer F: 700 (days 1–5)/3 (SCC) wks × 2 courses Stages III, IV D: 60 (day 1) Esophageal C: 70 (day 1) cancer F: 600 (days 1–5)/4 (SCC) wks × 2 courses Stage IV D: 75 (day 1) Esophageal cancer and C: 75 (day 1) F: 750 (days 1–5)/3 gastric cancer (AD) wks × 3 courses Stages II, III, IV D: 70 (day 1) Esophageal C: 70 (day 1) cancer F: 750 (days 1–5) (SCC) D: 75 (day 1) Stages IIA, C: 75 (day 1) IIB, III F: 750 (days 1–5)/3 wks × 3 courses D: 60 (day 1) Esophageal C:6 (days 1–5) cancer (SCC, AD) F: 350 (days 1–5)/3 wks × 2 courses Stages IIB, III, IVA, IVB (TNM6)

Takahashi [32]

Esophageal cancer (SCC) Stages III, IV Esophageal cancer (SCC) Stages III, IV

Target

References (first author)

Regimen (/m2)

45.2

–

30

9/40

29

43

42

50

II

I/II

II

II

II

Prospective intension-totreat

–

52

72.5

33.3

78.2

83.3

20

76

90

–

43.6

39

I/II

53.8

Cases, Grade 3/4 Grade 3/4 n leukopenia neutropenia (%) (%)

Phase

Table 5  Docetaxel, CDDP, and 5-Fu for advanced esophageal cancer

14.5

2.4

2.3

21

10

–

12.8

53.7

64.3

–

34.5 (confirmed cases)

72.5

83.3 (primary lesion)

66.6

Response Febrile neutropenia rate (%) (%)

26

51

12

17

9.8

–

–

–

25

–

–

40

–

Histopathological complete response rate (grade 3) (%)

–

Histopathological response rate (>grade 2) (%)

–

64.3

–

13.8

–

–

–

Dose reduction rate in the second cycle (%)

–

95.2

95

–

82.5

96.7

–

Protocol completion rate (%)

1154 Cancer Chemother Pharmacol (2016) 77:1153–1155

Esophageal cancer (SCC, AS, B) Stage IV

Hironaka [38]

32

II

D: 35 (days 1, 15) C:40 (days 1, 15) F: 400 (days 1–5, 15–19)

12.5

31.3

25.5

10/52

I/II

D: 30 (days 1, 15) C: 80 (day 1) F: 800 (days 1–5)/4 wks

9.1

Cases, Grade 3/4 Grade 3/4 n leukopenia neutropenia (%) (%)

Phase

Regimen (/m2)

0

0

90.3

62

Response Febrile neutropenia rate (%) (%)

53.2

–

Histopathological response rate (>grade 2) (%)

SCC squamous cell carcinoma, AD adenocarcinoma, AS adenosquamous carcinoma, B basaloid carcinoma, D docetaxel, C cisplatin, F fluorouracil

Current study Esophageal cancer (SCC) Stages II, III

Target

References (first author)

Table 5  continued

21.9

–

Histopathological complete response rate (grade 3) (%)

0

–

Dose reduction rate in the second cycle (%)

100

–

Protocol completion rate (%)

Cancer Chemother Pharmacol (2016) 77:1153–1155 1155

13